Cystic Fibrosis Weekly Update

Contents:

Plan A Didn’t Work — Now What?

Jul 24, 2020 09:00 am | Lara Govendo

I open my eyes, and the walls around me blur like a mirage. I whisper through my post-intubated raw throat: “Did it work?” My nurse replies: “No, they weren’t able to fix the problem.” Preliminary tears well up in my anesthesia-drunken stupor. She must be lying, I think to myself. I’m suddenly convinced that my […]
The post Plan A Didn’t Work — Now What? appeared first on Cystic Fibrosis News Today.

CF Patients in Wales Will Have Access to Kaftrio Under New Deal

Jul 24, 2020 07:00 am | Patricia Inacio, PhD

The Welsh government and Vertex Pharmaceuticals have reached an agreement that will allow access to the company’s Kaftrio (ivacaftor/tezacaftor/elexacaftor) for cystic fibrosis (CF) patients as soon as the medication is approved in Europe. Kaftrio is a triple combination therapy for the treatment of CF, designed to be used in a combination regimen with Kalydeco, also marketed by […]
The post CF Patients in Wales Will Have Access to Kaftrio Under New Deal appeared first on Cystic Fibrosis News Today.

ContraFect Given Up to $18.9M to Advance CF-370 for P. aeruginosa Infections

Jul 23, 2020 07:00 am | Ines Martins, PhD

ContraFect has been awarded to $18.9 million by the nonprofit investment group CARB-X to advance CF-370 as a potential treatment for Pseudomonas aeruginosa infections. These bacteria and the thick layer of biofilm they produce are a major cause of pulmonary exacerbations in cystic fibrosis (CF) patients. CARB-X, which stands for Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator, launched in 2016 as […]
The post ContraFect Given Up to $18.9M to Advance CF-370 for P. aeruginosa Infections appeared first on Cystic Fibrosis News Today.